info@marketresearchfuture.com   ­čô×  +1 (855) 661-4441(US)   ­čô×  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Metabolic Biomarker Testing Market Research Report Information By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders), Application (Drug Discovery, Nutrigenomics, Toxicology Testing, Personalized Medicine), Technique, End User ÔÇô Forecast To 2030


ID: MRFR/LS/4164-HCR | 90 Pages | Author: Rahul Gotadki| July 2024

Global Metabolic Biomarker Testing Market Overview


The Metabolic Biomarker Testing Market Size valued at USD 3.56 Billion in 2023. The Metabolic Biomarker Testing industry is projected to rise from USD 3.68 Billion in 2024 to USD 6.54 Billion by 2032, exhibiting a compound yearly growth rate (CAGR) of 9.23% during the forecast period (2024 - 2032).


Metabolic Biomarker Testing Market


There is an increasing demand for personalized medicines in the European and Americas region, the important factors for the growth of the metabolic biomarker testing market. Furthermore, the rising need for toxicology technologies, the increasing government research funding and initiatives, escalated R&D activities across various sectors are fueling the market growth worldwide.


Metabolic Biomarker Testing Market Trends


Metabolic biomarker testing is the process of identification and quantification of metabolites in a biological system. The steps involved in metabolic biomarker analysis are profiling, identification, quantification, and interpretation. Most healthcare professionals use diagnostic tests to clarify and support their clinical decision making.


The recent technological advancement is the key strategy implemented by major players to expand their reach in the global market and fortify their product portfolio. For instance, in November 2016, Metabolon, Inc. launched its novel product the Meta IMD test for diagnosing any hereditary metabolic issues. Moreover, in May 2016, Agilent Technologies Inc. global launch of the Agilent 5110 ICP-OES, an atomic spectroscopy.


Furthermore, the factors such as the rising demand for personalized medicine, increasing need for accurate diagnosis of diseases, increasing pharmaceutical and biotech R&D expenditure, huge investments by government & private players in the R&D are driving the market growth. Lack of awareness of metabolic biomarker and lack of skilled personnel to conduct these procedure are likely to restrain the market growth over the forecast period.


Metabolic Biomarker Testing Market Segmentation


The metabolic biomarker testing market is segmented on the basis of techniques, indications, application, and end user.


Metabolic Biomarker Testing Techniques Insights


On the basis of the techniques, the metabolic biomarker testing market is segmented into separation techniques, detection techniques. The separation techniques are categorized into liquid chromatography, gas chromatography, capillary chromatography. Moreover, the liquid chromatography segment is classified into high-performance liquid chromatography and ultra-performance liquid chromatography. Furthermore, detection techniques are divided into mass spectrometry, multivariate analysis, and spectroscopy. On the basis of detection techniques, spectroscopy is further classified into nuclear magnetic resonance spectroscopy, and Fourier transform infrared spectroscopy.


Metabolic Biomarker Testing Indication Insights


On the basis of the indication, the metabolic biomarker testing market is segmented into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others.


Metabolic Biomarker Testing Application Insights


On the basis of the application, the metabolic biomarker testing market is segmented into drug discovery or drug assessment, nutrigenomics, toxicology testing, personalized medicine, functional genomics, and others.


Metabolic Biomarker Testing End user Insights


On the basis of the end user, the metabolic biomarker testing market is segmented into pharma & biotech companies, diagnostic tool companies, healthcare it/big data companies, clinical laboratories, and others.


Metabolic Biomarker Testing Market Regional Analysis


The metabolic biomarker testing market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominated the metabolic biomarker testing market owing to the increasing applications of NGS procedures. The U.S. is the most prominent market in the region. Rising research activities undertaken by various biological and pharmaceutical industries in the region is anticipated to augment the metabolic biomarker testing market over the forecast period.


The European region is responsible for substantial market share in 2016. The European metabolic biomarker market is predicted to grow throughout the forecast period due to the presence of huge number of service provider for analytical equipment is expected to drive the metabolic biomarker market in this region.


The Asia Pacific region is likely to witness significant growth owing to the expansion of biotechnology and pharmaceutical industries in the region are some of the key factors driving the growth of the metabolic biomarker market.


The Middle East and Africa is expected to showcase healthy growth over the coming years. Weak healthcare and research infrastructure, lack of awareness about genetic diseases, limited availability of products and services, and traditional healthcare practices are some factors affecting the growth of the Middle East and African metabolic biomarker testing market.


Metabolic Biomarker Testing Market Key Players


Some of key the players in the metabolic biomarker testing market are 



  • Agilent Technologies, Inc. (U.S.)

  • Bio-Rad Laboratories, Inc. (U.S.)

  • Bruker Corporation (U.S.)

  • Danaher Corporation (U.S.)

  • Waters Corporation (U.S.)

  • Shimadzu Corporation (Japan)

  • Biocrates Life Sciences AG (Austria)

  • Thermo Fisher Scientific, Inc. (U.S.)

  • Human Metabolome Technologies Inc. (Japan)

  • LECO Corporation (U.S.

  • Metabolon Inc. (U.S.)

Report Attribute/Metric Details
Market Size 2023 USD 3.56 billion
Market Size 2024 USD 3.68 billion
Market Size 2032 USD 6.54 billion
Compound Annual Growth Rate (CAGR) 9.23 % (2024-2032)
Base Year 2023
Market Forecast Period 2024-2032
Historical Data 2018 & 2021
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Indication, Application, End-User, and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), Waters Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Shimadzu Corporation (Japan), Biocrates Life Sciences AG (Austria), Human Metabolome Technologies Inc. (Japan), LECO Corporation (U.S., Metabolon Inc. (U.S.)
Key Market Opportunities Increasing demand for personalized medicines
Key Market Dynamics Increasing government research funding and initiatives, escalated R&D activities


Frequently Asked Questions (FAQ) :

Metabolic Biomarker Testing is the process of identification and quantification of metabolites in a biological system.

The market is expected to exhibit a solid 9.23% CAGR over the forecast period from 2024 to 2032.

The growing demand for personalized medication is a major driver for the Metabolic Biomarker Testing Market.

The Americas dominate the global market due to the strong position of the healthcare sector in the region.

Leading players in the Metabolic Biomarker Testing include Agilent, Bio-Rad Laboratories, and Bruker Corporation, among others.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.